Financial Architects (New Jersey)’s BioCryst Pharmaceuticals BCRX Stock Holding History

Financial Architects (New Jersey)’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-30	Closed	–	–	1210
2019 Q1	$0	Hold	30	–	–	﹤0.01%	1421
2018 Q4	$0	Hold	30	–	–	﹤0.01%	1335
2018 Q3	$0	Hold	30	–	–	﹤0.01%	1415
2018 Q2	$0	Hold	30	–	–	﹤0.01%	1335
2018 Q1	$0	Hold	30	–	–	﹤0.01%	1397
2017 Q4	$0	Hold	30	–	–	﹤0.01%	1488
2017 Q3	$0	Hold	30	–	–	﹤0.01%	1482
2017 Q2	$0	Hold	30	–	–	﹤0.01%	1517
2017 Q1	$0	Hold	30	–	–	﹤0.01%	1561
2016 Q4	$0	Hold	30	–	–	﹤0.01%	1393
2016 Q3	$0	Hold	30	–	–	﹤0.01%	1446
2016 Q2	$0	Buy	+30	New	+$93	﹤0.01%	1429

Other funds holding BCRX

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VMI

VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

Financial Architects (New Jersey)'s BCRX Position: Q2 2019 in Review

Financial Architects (New Jersey) sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2019, closing a stake of 30 shares.

Financial Architects (New Jersey) first reported a position in BCRX in Q2 2016 and held it in 12 quarters. The position peaked at $0 in Q1 2019. 116 funds tracked by Wall St. Rank hold BCRX as of Q2 2019.

Financial Architects (New Jersey) reported no remaining BioCryst Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
Financial Architects (New Jersey) sold 30 BioCryst Pharmaceuticals shares in Q2 2019.
Financial Architects (New Jersey) first reported a position in BioCryst Pharmaceuticals in Q2 2016 and held it in 12 quarters.
Financial Architects (New Jersey)'s BioCryst Pharmaceuticals position peaked at $0 in Q1 2019.
116 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2019.

Based on Financial Architects (New Jersey)'s 13F filing for Q2 2019, filed 14 Aug 2019.